

Additional file 1, Table S1.

Characteristics of patients analyzed for *TP53* mutations compared with the entire BIG-02-98 cohort.

		p53 study N=520	BIG-02-98 N=2887
Age	Median	49	49
	Range	26-70	21-70
	<35	34 (6.5%)	195 (6.8%)
	35-49	255 (49.0%)	1346 (46.6%)
	50-65	213 (41.0%)	1231 (42.6%)
	>65	18 (3.5%)	115 (4.0%)
Menopausal status	Pre-menopausal	286 (55.0%)	1552 (53.8%)
	Post-menopausal	206 (39.6%)	1173 (40.6%)
	missing	28 (5.4%)	162 (5.6%)
Histopathology	Infiltrating ductal ca.	424 (81.5%)	1045 (79.5%)
	Infiltrating lobular ca.	53 (10.2%)	174 (13.2%)
	Other	43 (8.3%)	96 (7.3%)
Histopathologic grade	G1	50 (9.6%)	91 (6.9%)
	G2	242 (46.5%)	566 (43.0%)
	G3	215 (41.3%)	609 (46.3%)
	missing	13 (2.5%)	49 (3.7%)
Number of positive lymph nodes	1-3	272 (52.3%)	1567 (54.3%)
	> 4	248 (47.7%)	1320 (45.7%)
ER/PR status	ER+/PR+	296 (56.9%)	1482 (51.3%)
	ER+/PR-	48 (9.2%)	342 (11.8%)
	ER-/PR-	114 (21.9%)	685 (23.7%)
	other	62 (11.9%)	378 (13.1%)
IHC subtypes	Luminal A	84 (16.1%)	294 (10.2%)
	Luminal B	315 (60.6%)	1034 (35.8%)
	HER2	32 (6.2%)	149 (5.2%)
	Triple negative	66 (12.7%)	300 (10.2%)
	missing	23 (4.4%)	1110 (38.4%)
Hormonotherapy (HT) usage	Received HT	394 (75.8%)	2126 (73.6%)